{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:54:53Z","timestamp":1793926493339,"version":"4.8.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2019,10,1]]},"DOI":"10.1001\/jamacardio.2019.2851","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T17:28:35Z","timestamp":1567013315000},"page":"969","source":"Crossref","is-referenced-by-count":47,"title":["Cost-effectiveness of Low-density Lipoprotein Cholesterol Level\u2013Guided Statin Treatment in Patients With Borderline Cardiovascular Risk"],"prefix":"10.1001","volume":"4","author":[{"given":"Ciaran N.","family":"Kohli-Lynch","sequence":"first","affiliation":[{"name":"Division of General Medicine, Columbia University Medical Center, New York, New York"},{"name":"Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon K.","family":"Bellows","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thanassoulis","sequence":"additional","affiliation":[{"name":"Division of Cardiology, McGill University, Quebec City, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Pletcher","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Biostatistics, University of California at San Francisco School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vittinghoff","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Biostatistics, University of California at San Francisco School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pencina","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Kazi","sequence":"additional","affiliation":[{"name":"Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan D.","family":"Sniderman","sequence":"additional","affiliation":[{"name":"Division of Cardiology, McGill University, Quebec City, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Moran","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"hoi190047r1","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease.","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"25","key":"hoi190047r2","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"139","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hoi190047r4","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","article-title":"2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult.","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"issue":"25","key":"hoi190047r6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"19","key":"hoi190047r7","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1001\/jama.2016.15450","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement.","volume":"316","author":"Bibbins-Domingo","year":"2016","journal-title":"JAMA"},{"issue":"9841","key":"hoi190047r8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"issue":"15","key":"hoi190047r9","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/jama.2018.2525","article-title":"Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis.","volume":"319","author":"Navarese","year":"2018","journal-title":"JAMA"},{"issue":"16","key":"hoi190047r10","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1161\/CIRCULATIONAHA.115.018383","article-title":"Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease.","volume":"133","author":"Thanassoulis","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"hoi190047r11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1001\/jamacardio.2018.3476","article-title":"A long-term benefit approach vs standard risk-based approaches for statin eligibility in primary prevention.","volume":"3","author":"Thanassoulis","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"2","key":"hoi190047r12","doi-asserted-by":"publisher","first-page":"e004316","DOI":"10.1161\/JAHA.116.004316","article-title":"Population impact & efficiency of benefit-targeted versus risk-targeted statin prescribing for primary prevention of cardiovascular disease.","volume":"6","author":"Pletcher","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"43","key":"hoi190047r13","first-page":"2975","article-title":"Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment.","volume":"36","author":"Soran","year":"2015","journal-title":"Eur Heart J"},{"issue":"12","key":"hoi190047r14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1161\/CIRCULATIONAHA.117.027067","article-title":"Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke.","volume":"136","author":"Heller","year":"2017","journal-title":"Circulation"},{"issue":"9","key":"hoi190047r15","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/jama.1991.03460090093039","article-title":"Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.","volume":"265","author":"Goldman","year":"1991","journal-title":"JAMA"},{"issue":"4","key":"hoi190047r16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.7326\/0003-4819-150-4-200902170-00005","article-title":"Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.","volume":"150","author":"Pletcher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"hoi190047r17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1161\/CIRCULATIONAHA.110.986349","article-title":"Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.","volume":"124","author":"Lazar","year":"2011","journal-title":"Circulation"},{"issue":"11","key":"hoi190047r18","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1093\/aje\/kwy139","article-title":"Harmonization of respiratory data from 9 US population-based cohorts: the NHLBI Pooled Cohorts Study.","volume":"187","author":"Oelsner","year":"2018","journal-title":"Am J Epidemiol"},{"issue":"7","key":"hoi190047r19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease.","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"},{"issue":"12","key":"hoi190047r20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1161\/CIRCULATIONAHA.113.007787","article-title":"Trends in hospitalizations and outcomes for acute cardiovascular disease and stroke, 1999-2011.","volume":"130","author":"Krumholz","year":"2014","journal-title":"Circulation"},{"key":"hoi190047r22","article-title":"Use of a pooled cohort to impute cardiovascular disease risk factors across the adult life course [published online December 7, 2018].","author":"Zeki Al Hazzouri","journal-title":"Int J Epidemiol"},{"issue":"9753","key":"hoi190047r23","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"9716","key":"hoi190047r24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"hoi190047r25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jama.2015.6822","article-title":"Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease.","volume":"314","author":"Pandya","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"hoi190047r26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/2047487314525531","article-title":"What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? systematic review of randomized placebo-controlled trials to aid individual patient choice.","volume":"21","author":"Finegold","year":"2014","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"hoi190047r27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.7326\/M18-0808","article-title":"Statins and multiple noncardiovascular outcomes: umbrella review of meta-analyses of observational studies and randomized controlled trials.","volume":"169","author":"He","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"hoi190047r28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","article-title":"Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.","volume":"104","author":"Mills","year":"2011","journal-title":"QJM"},{"issue":"2","key":"hoi190047r29","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association.","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"hoi190047r30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study.","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"hoi190047r31","article-title":"Finding the balance between benefits and harms when using statins for primary prevention of cardiovascular disease: a modeling study [published online December 4, 2018].","author":"Yebyo","journal-title":"Ann Intern Med"},{"key":"hoi190047r32","doi-asserted-by":"publisher","first-page":"d1672","DOI":"10.1136\/bmj.d1672","article-title":"Statin treatment for primary prevention of vascular disease: whom to treat? cost-effectiveness analysis.","volume":"342","author":"Greving","year":"2011","journal-title":"BMJ"},{"issue":"10","key":"hoi190047r34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"22","key":"hoi190047r35","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1161\/CIR.0000000000000042","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.","volume":"129","author":"Anderson","year":"2014","journal-title":"Circulation"},{"issue":"15","key":"hoi190047r36","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1161\/CIRCULATIONAHA.110.947960","article-title":"Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy.","volume":"122","author":"Lee","year":"2010","journal-title":"Circulation"},{"issue":"14","key":"hoi190047r37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19140","article-title":"Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.","volume":"19","author":"Claxton","year":"2015","journal-title":"Health Technol Assess"},{"issue":"3","key":"hoi190047r38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jval.2017.10.006","article-title":"Resolving the \u201ccost-effective but unaffordable\u201d paradox: estimating the health opportunity costs of nonmarginal budget impacts.","volume":"21","author":"Lomas","year":"2018","journal-title":"Value Health"},{"issue":"8","key":"hoi190047r39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-level cost-effectiveness thresholds: initial estimates and the need for further research.","volume":"19","author":"Woods","year":"2016","journal-title":"Value Health"},{"key":"hoi190047r3","first-page":"79","volume-title":"Risk Estimation and the Prevention of Cardiovascular Disease","year":"2017"},{"key":"hoi190047r5","unstructured":"National Clinical Guideline Centre (UK). Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. London, United Kingdom: National Institute for Health and Care Excellence; 2014. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK248067\/. Accessed October 20, 2018."},{"key":"hoi190047r21","unstructured":"Centers for Disease Control and Prevention; National Center for Health Statistics. National Health and Nutrition Examination Survey data. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention; 1999. https:\/\/wwwn.cdc.gov\/Nchs\/Nhanes\/1999-2000\/DSPI.htm. Revised December 2016. Accessed June 15, 2018."},{"key":"hoi190047r33","unstructured":"Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey 2015. http:\/\/meps.ahrq.gov\/mepsweb\/. Published 2015. Accessed November 30, 2018."},{"key":"hoi190047r40","unstructured":"Centers for Medicare & Medicaid Services. License for Use of Current Procedural Terminology, Fourth Edition (\u201cCPT\u201d). http:\/\/www.cms.gov\/apps\/physician-fee-schedule\/search\/search-results.aspx?Y=0&T=0&HT=0&CT=3&H1=99212&M=5 Published April 2018. Accessed June 22, 2018."}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2748763\/jamacardiology_kohlilynch_2019_oi_190047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T21:16:09Z","timestamp":1571260569000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2748763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.2851","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,1]]}}}